NURS 6630 Week 4 Assignment:
THE ASSIGNMENT: 5 PAGES
For this assignment, you will develop a patient medication guide for treatment of depressive disorders in a vulnerable population (your choice for one vulnerable patient population to choose from: children, adolescents, older adults, dementia patients, pregnant women or one not listed of your choice!). Be sure to use language appropriate for your audience (patient, caregiver, parent, etc.). You will include non-copyright images and/or information tables to make your patient medication guide interesting and appealing. Limit your patient medication guide to 5 pages. You will create this guide as an assignment; therefore, a title page, introduction, conclusion, and reference page are required. You must include a minimum of 3 scholarly supporting resources outside of your course provided resources.
In your patient guide, include a discussion on the following:
- Depressive disorder causes and symptoms
- How depression is diagnosed for the vulnerable population of your choice, why is this population considered vulnerable
- Medication treatment options including risk vs benefits; side effects; FDA approvals for the vulnerable population of your choice
- Medication considerations of medication examples prescribed (see last bullet item)
- What is important to monitor in terms of labs, comorbid medical issues with why important for monitoring
- Special Considerations (you must be specific, not general and address at least one for EACH category; you must demonstrate critical thinking beyond basics of HIPPA and informed consent!): legal considerations, ethical considerations, cultural considerations, social determinants of health
- Where to follow up in your local community for further information
- Provide 3 examples of how to write a proper prescription that you would provide to the patient or transmit to the pharmacy.
Note: Support your rationale with a minimum of five academic resources. While you may use the course text to support your rationale, (Massachusetts General Hospital Psychopharmacology and Neurotherapeutics 2016, Stern, Theodore A.) it will not count toward the resource requirement. You should be utilizing the primary and secondary literature.
- Baek, J. H., Nierenberg, A. A., & Fava, M. (2016). Pharmacological approaches to treatment-resistant depression. In T. A. Stern, M. Favo, T. E. Wilens, & J. F. Rosenbaum. (Eds.), Massachusetts General Hospital psychopharmacology and neurotherapeutics (pp. 44–47). Elsevier.
- Fava, M., & Papakostas, G. I. (2016). Antidepressants. In T. A. Stern, M. Favo, T. E. Wilens, & J. F. Rosenbaum. (Eds.), Massachusetts General Hospital psychopharmacology and neurotherapeutics (pp. 27–43). Elsevier.
- American Psychiatric Association. (2013). Diagnostic and statistical manual of mental disorders (5th ed.) Links to an external site.. https://doi.org/10.1176/appi.books.9780890425596
- Howland, R. H. (2008a). Sequenced Treatment Alternatives to Relieve Depression (STAR*D). Part 1: Study design. Journal of Psychosocial Nursing and Mental Health Services Links to an external site., 46(9), 21–24. https://doi.org/10.3928/02793695-20080901-06
- Howland, R. H. (2008b). Sequenced Treatment Alternatives to Relieve Depression (STAR*D). Part 2: Study outcomes. Journal of Psychosocial Nursing and Mental Health Services Links to an external site., 46(10), 21–24. https://doi.org/10.3928/02793695-20081001-05
- Lorberg, B., Davico, C., Martsenkovskyi, D., & Vitiello, B. (2019). Principles in using psychotropic medication in children and adolescents. In J. M. Rey & A. Martin (Eds.), IACAPAP e-textbook of child and adolescent mental health Links to an external site.. https://iacapap.org/_Resources/Persistent/45bdffb25befc353c9f61988e82105029504ab85/A.7-Psychopharmacology-2019.1.pdf
- Magellan Health. (2013). com/media/445492/magellan-psychotropicdrugs-0203141.pdf” target=”_blank” rel=”noreferrer noopener”>Appropriate use of psychotropic drugs in children and adolescents: A clinical monograph Links to an external site.. http://www.magellanhealth.com/media/445492/magellan-psychotropicdrugs-0203141.pdf
- Poznanski, E. O., & Mokros, H. B. (1996). Child depression rating scale—Revised Links to an external site.. Western Psychological Services.
- Rao, U. (2013). Biomarkers in pediatric depression. Depression & Anxiety Links to an external site., 30(9), 787–791. https://doi.org/10.1002/da.22171
- Yasuda, S. U., Zhang, L. & Huang, S.-M. (2008). The role of ethnicity in variability in response to drugs: Focus on clinical pharmacology studies. Clinical Pharmacology & Therapeutics Links to an external site., 84(3), 417–423. https://web.archive.org/web/20170809004704/https://www.fda.gov/downloads/Drugs/ScienceResearch/…/UCM085502.pdf
- U.S. Food & Drug Administration. (n.d.). Drugs@FDA: FDA-approved drugs Links to an external site.. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm
Note: To access the following medications, use the Drugs@FDA resource. Type the name of each medication in the keyword search bar. Select the hyperlink related to the medication name you searched. Review the supplements provided and select the package label resource file associated with the medication you searched. If a label is not available, you may need to conduct a general search outside of this resource provided. Be sure to review the label information for each medication as this information will be helpful for your review in preparation for your Assignments.
Review the following medications:
|amitriptyline bupropion citalopram clomipramine desipramine desvenlafaxine doxepin duloxetine escitalopram fluoxetine fluvoxamine||imipramine ketamine mirtazapine nortriptyline paroxetine selegiline sertraline trazodone venlafaxine vilazodone vortioxetine|